OUR THERAPEUTIC AREAS
To discover new treatments that improve patients’ lives, Servier invests close to 20% of its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development efforts in therapeutic areas where needs are substantial.
ONCOLOGY
Cancer causes more than one in six of all deaths, making it the second leading cause of death throughout the world¹. To address the growing need for therapeutic solutions, we allocate nearly 70% of our R&D budget to oncology. Our objective is to develop precision therapies that aim to transform the lives of patients affected by cancer. We are a focused and innovative player in the treatment of digestive cancers, brain tumors and hematological cancers.
[1] World Health Organization (WHO), Cancer – Fact sheet, February 2022.
CARDIOMETABOLISM
Cardiovascular diseases and their complications are the leading cause of death worldwide: with 19.8 million deaths in 2022, they represent one third of total global mortality1. In this area, we take a holistic, patient-centered approach. As the world’s leading pharmaceutical group in hypertension and ranking fifth in cardiology2, our objective is to innovate in order to transform the lives of people living with chronic diseases. We accomplish this in particular through Single Pill Combinations (SPCs), which combine several medicines into a single tablet. We also develop innovative digital services to improve therapeutic adherence.
[1] World Health Organization (WHO), Diabetes – Fact sheet, November 2024.
[2] IQVIA, Analytics Link / World, 84 countries – MAT Q3-2025.
NEUROLOGY
Rare neurological disorders affect between 130 and 220 million people worldwide1; approximately 600 rare neurological conditions have been identified2. At Servier, we focus on discovering new medicines that slow or halt disease progression in rare neurological disorders and significantly improve patient quality of life. To reach this goal, we are building on our core areas of expertise: small molecules, monoclonal antibodies and antisense oligonucleotides (ASOs). That’s why we have defined six clusters of diseases to concentrate on: rare refractory epilepsies, rare movement disorders, neuromuscular disorders, genetically-driven autism spectrum disorders (ASD), leukodystrophies and peripheral neuropathies
[1] Mancuso M. et al., Neurological Sciences, 2020.
[2] Neurological Disorders Market, DelveInsight Business Research, January 2025.